Telstar Develops High-Containment Barrier Systems for Komipharm

November 13, 2013

The systems are designed for the manufacture of oncology products and to research new biotech products.

The Technology Centre for Barrier Isolation Systems of Telstar, based in the UK, has developed two high-containment barrier systems for Komipharm Pharmaceuticals, a Korean producer of oncology products and veterinary medicines supplying the Asian market. Komipharm will use these systems, one for API sampling and the other for QC sample handling in its new facility in Cheongwon, Chungcheongbuk-do, South Korea.

The systems have been designed to provide a high level of containment to protect operators working with hazardous products during the manufacturing process of highly potent APIs. These systems will also be used in the development of vaccines by genetic technology. The containment systems run at negative pressure to the surrounding room and provide operator and environmental protection according to the standard ISO 7 classification inside the isolator.

Source: Telstar